Miguel Jimenez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miguel Jimenez has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Traverso
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
9 shared publications - Ana Laura Ortega Granados
Hospital Universitario de Jaén, Jaén, Spain
4 shared publications - Pedro Sánchez-Rovira
Department of Medical Oncology, Complejo Hospitalario de Jaén, 23007 Jaén, Spain
4 shared publications - Rabia Tugce Yazicigil
Department of Electrical and Computer Engineering, Boston University, Boston, MA, USA
4 shared publications - Virginia W. Cornish
Department of Chemistry, Columbia University; New York, NY USA
4 shared publications - Anantha P. Chandrakasan
Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, USA
3 shared publications
Latest Publications
- Open Access
Passive Cell-Flux Partitioning Enables Single-Cell-Constrained Impedance Sensing From High-Density Microbial Cultures
Fermentation is a process through which microorganisms are used to transform basic molecules into high value substances in various applications such as biopharma, food production, and biofuel generation. In such processes, monitoring the health of microbial cells is essential, as it is a key factor in the final product yield. Traditional methods of assessing the health of fermenter populations have involved manually extracting samples from the fermenter for benchtop testing, which lacked the accuracy and efficacy of real-time continuous measurements. This has opened the door for inline sensors to be integrated into fermenters for continuous measurement; including microfluidic based Electrochemical Impedance Spectroscopy (EIS). EIS utilizes a range of frequencies to gain insight into the characteristics of microbial populations, such as cell size and membrane capacitance. EIS cytometry, in particular, has emerged as a relevant tool, as it enables single-cell level detection in real-time. However, current EIS cytometry devices cannot be deployed directly within fermenters due to the high cell density conditions. This has limited EIS analysis in fermenters to bulk measurements averaged across a population. Here, we present a microfluidic chip that uses passive cell-flux-partitioning geometry to direct cells from high-density culture through a single-cell-constrained flow path containing integrated impedance-sensing electrodes. The proposed chip combines geometric channel design and embedded electrodes to enable continuous impedance measurements from cell-containing flow while operating at input cell densities on the scale of 10 9 CFU/mL. This work demonstrates a first step toward integrating single-cell-constrained microfluidic handling with impedance sensing for inline monitoring in industrial biomanufacturing.
Open AccessPassive Cell-Flux Partitioning Enables Single-Cell-Constrained Impedance Sensing From High-Density Microbial Cultures
Fermentation is a process through which microorganisms are used to transform basic molecules into high value substances in various applications such as biopharma, food production, and biofuel generation. In such processes, monitoring the health of microbial cells is essential, as it is a key factor in the final product yield. Traditional methods of assessing the health of fermenter populations have involved manually extracting samples from the fermenter for benchtop testing, which lacked the accuracy and efficacy of real-time continuous measurements. This has opened the door for inline sensors to be integrated into fermenters for continuous measurement; including microfluidic based Electrochemical Impedance Spectroscopy (EIS). EIS utilizes a range of frequencies to gain insight into the characteristics of microbial populations, such as cell size and membrane capacitance. EIS cytometry, in particular, has emerged as a relevant tool, as it enables single-cell level detection in real-time. However, current EIS cytometry devices cannot be deployed directly within fermenters due to the high cell density conditions. This has limited EIS analysis in fermenters to bulk measurements averaged across a population. Here, we present a microfluidic chip that uses passive cell-flux-partitioning geometry to direct cells from high-density culture through a single-cell-constrained flow path containing integrated impedance-sensing electrodes. The proposed chip combines geometric channel design and embedded electrodes to enable continuous impedance measurements from cell-containing flow while operating at input cell densities on the scale of 10 9 CFU/mL. This work demonstrates a first step toward integrating single-cell-constrained microfluidic handling with impedance sensing for inline monitoring in industrial biomanufacturing.
- Top Cited PapersOpen Access
- 15 August 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (10) , 1491-1501
Designing lipid nanoparticles using a transformer-based neural network
The RNA medicine revolution has been spurred by lipid nanoparticles (LNPs). The effectiveness of an LNP is determined by its lipid components and their ratios; however, experimental optimization is laborious and does not explore the full design space. Computational approaches such as deep learning can be greatly beneficial, but the composite nature of LNPs limits the effectiveness of existing single molecule-based algorithms to LNPs. Addressing this, our approach integrates the multi-component and multimodal features of composite formulations such as LNPs to predict their performance in an end-to-end manner. Here we generate one of the largest LNP datasets (LANCE) by varying LNP formulations to train our deep learning model, COMET. This transformer-based neural network not only accurately predicts the efficacy of LNPs but is adaptable to non-canonical LNP formulations such as those with two ionizable lipids and polymeric materials. Furthermore, COMET can predict LNP performance in a cell line outside of LANCE and predict LNP stability during lyophilization using only small training datasets. Experimental validation showed that our approach can identify LNPs that exhibit strong protein expression in vitro and in vivo, promising accelerated development of nucleic acid therapies with extensive potential across therapeutic and manufacturing applications.
- 15 August 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (10) , 1491-1501
Top Cited PapersOpen AccessDesigning lipid nanoparticles using a transformer-based neural network
The RNA medicine revolution has been spurred by lipid nanoparticles (LNPs). The effectiveness of an LNP is determined by its lipid components and their ratios; however, experimental optimization is laborious and does not explore the full design space. Computational approaches such as deep learning can be greatly beneficial, but the composite nature of LNPs limits the effectiveness of existing single molecule-based algorithms to LNPs. Addressing this, our approach integrates the multi-component and multimodal features of composite formulations such as LNPs to predict their performance in an end-to-end manner. Here we generate one of the largest LNP datasets (LANCE) by varying LNP formulations to train our deep learning model, COMET. This transformer-based neural network not only accurately predicts the efficacy of LNPs but is adaptable to non-canonical LNP formulations such as those with two ionizable lipids and polymeric materials. Furthermore, COMET can predict LNP performance in a cell line outside of LANCE and predict LNP stability during lyophilization using only small training datasets. Experimental validation showed that our approach can identify LNPs that exhibit strong protein expression in vitro and in vivo, promising accelerated development of nucleic acid therapies with extensive potential across therapeutic and manufacturing applications.
- Top Cited Papers
- 26 February 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (8) , 1240-1253
Radioprotection of healthy tissue via nanoparticle-delivered mRNA encoding for a damage-suppressor protein found in tardigrades
Patients undergoing radiation therapy experience debilitating side effects because of toxicity arising from radiation-induced DNA strand breaks in normal peritumoural cells. Here, inspired by the ability of tardigrades to resist extreme radiation through the expression of a damage-suppressor protein that binds to DNA and reduces strand breaks, we show that the local and transient expression of the protein can reduce radiation-induced DNA damage in oral and rectal epithelial tissues (which are commonly affected during radiotherapy for head-and-neck and prostate cancers, respectively). We used ionizable lipid nanoparticles supplemented with biodegradable cationic polymers to enhance the transfection efficiency and delivery of messenger RNA encoding the damage-suppressor protein into buccal and rectal tissues. In mice with orthotopic oral cancer, messenger RNA-based radioprotection of normal tissue preserved the efficacy of radiation therapy. The strategy may be broadly applicable to the protection of healthy tissue from DNA-damaging agents.
- 26 February 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (8) , 1240-1253
Top Cited PapersRadioprotection of healthy tissue via nanoparticle-delivered mRNA encoding for a damage-suppressor protein found in tardigrades
Patients undergoing radiation therapy experience debilitating side effects because of toxicity arising from radiation-induced DNA strand breaks in normal peritumoural cells. Here, inspired by the ability of tardigrades to resist extreme radiation through the expression of a damage-suppressor protein that binds to DNA and reduces strand breaks, we show that the local and transient expression of the protein can reduce radiation-induced DNA damage in oral and rectal epithelial tissues (which are commonly affected during radiotherapy for head-and-neck and prostate cancers, respectively). We used ionizable lipid nanoparticles supplemented with biodegradable cationic polymers to enhance the transfection efficiency and delivery of messenger RNA encoding the damage-suppressor protein into buccal and rectal tissues. In mice with orthotopic oral cancer, messenger RNA-based radioprotection of normal tissue preserved the efficacy of radiation therapy. The strategy may be broadly applicable to the protection of healthy tissue from DNA-damaging agents.
- 5 July 2024
- Published by Springer Nature in Nature Materials
- Vol. 23 (10) , 1436-1443
Synthetic extremophiles via species-specific formulations improve microbial therapeutics
Microorganisms typically used to produce food and pharmaceuticals are now being explored as medicines and agricultural supplements. However, maintaining high viability from manufacturing until use remains an important challenge, requiring sophisticated cold chains and packaging. Here we report synthetic extremophiles of industrially relevant gram-negative bacteria (Escherichia coli Nissle 1917, Ensifer meliloti), gram-positive bacteria (Lactobacillus plantarum) and yeast (Saccharomyces boulardii). We develop a high-throughput pipeline to define species-specific materials that enable survival through drying, elevated temperatures, organic solvents and ionizing radiation. Using this pipeline, we enhance the stability of E. coli Nissle 1917 by more than four orders of magnitude over commercial formulations and demonstrate its capacity to remain viable while undergoing tableting and pharmaceutical processing. We further show, in live animals and plants, that synthetic extremophiles remain functional against enteric pathogens and as nitrogen-fixing plant supplements even after exposure to elevated temperatures. This synthetic, material-based stabilization enhances our capacity to apply microorganisms in extreme environments on Earth and potentially during exploratory space travel.
- 5 July 2024
- Published by Springer Nature in Nature Materials
- Vol. 23 (10) , 1436-1443
Synthetic extremophiles via species-specific formulations improve microbial therapeutics
Microorganisms typically used to produce food and pharmaceuticals are now being explored as medicines and agricultural supplements. However, maintaining high viability from manufacturing until use remains an important challenge, requiring sophisticated cold chains and packaging. Here we report synthetic extremophiles of industrially relevant gram-negative bacteria (Escherichia coli Nissle 1917, Ensifer meliloti), gram-positive bacteria (Lactobacillus plantarum) and yeast (Saccharomyces boulardii). We develop a high-throughput pipeline to define species-specific materials that enable survival through drying, elevated temperatures, organic solvents and ionizing radiation. Using this pipeline, we enhance the stability of E. coli Nissle 1917 by more than four orders of magnitude over commercial formulations and demonstrate its capacity to remain viable while undergoing tableting and pharmaceutical processing. We further show, in live animals and plants, that synthetic extremophiles remain functional against enteric pathogens and as nitrogen-fixing plant supplements even after exposure to elevated temperatures. This synthetic, material-based stabilization enhances our capacity to apply microorganisms in extreme environments on Earth and potentially during exploratory space travel.
- 3 June 2024
- Published by Springer Nature in Nature Reviews Materials
- Vol. 9 (11) , 808-821
Advanced material technologies for space and terrestrial medicine
- 3 June 2024
- Published by Springer Nature in Nature Reviews Materials
- Vol. 9 (11) , 808-821
Advanced material technologies for space and terrestrial medicine
- Top Cited PapersOpen Access
- 27 February 2024
- Published by Springer Nature in Nature Materials
- Vol. 23 (9) , 1292-1299
Drinkable in situ-forming tough hydrogels for gastrointestinal therapeutics
Pills are a cornerstone of medicine but can be challenging to swallow. While liquid formulations are easier to ingest, they lack the capacity to localize therapeutics with excipients nor act as controlled release devices. Here we describe drug formulations based on liquid in situ-forming tough (LIFT) hydrogels that bridge the advantages of solid and liquid dosage forms. LIFT hydrogels form directly in the stomach through sequential ingestion of a crosslinker solution of calcium and dithiol crosslinkers, followed by a drug-containing polymer solution of alginate and four-arm poly(ethylene glycol)-maleimide. We show that LIFT hydrogels robustly form in the stomachs of live rats and pigs, and are mechanically tough, biocompatible and safely cleared after 24 h. LIFT hydrogels deliver a total drug dose comparable to unencapsulated drug in a controlled manner, and protect encapsulated therapeutic enzymes and bacteria from gastric acid-mediated deactivation. Overall, LIFT hydrogels may expand access to advanced therapeutics for patients with difficulty swallowing.
- 27 February 2024
- Published by Springer Nature in Nature Materials
- Vol. 23 (9) , 1292-1299
Top Cited PapersOpen AccessDrinkable in situ-forming tough hydrogels for gastrointestinal therapeutics
Pills are a cornerstone of medicine but can be challenging to swallow. While liquid formulations are easier to ingest, they lack the capacity to localize therapeutics with excipients nor act as controlled release devices. Here we describe drug formulations based on liquid in situ-forming tough (LIFT) hydrogels that bridge the advantages of solid and liquid dosage forms. LIFT hydrogels form directly in the stomach through sequential ingestion of a crosslinker solution of calcium and dithiol crosslinkers, followed by a drug-containing polymer solution of alginate and four-arm poly(ethylene glycol)-maleimide. We show that LIFT hydrogels robustly form in the stomachs of live rats and pigs, and are mechanically tough, biocompatible and safely cleared after 24 h. LIFT hydrogels deliver a total drug dose comparable to unencapsulated drug in a controlled manner, and protect encapsulated therapeutic enzymes and bacteria from gastric acid-mediated deactivation. Overall, LIFT hydrogels may expand access to advanced therapeutics for patients with difficulty swallowing.
- Top Cited Papers
- 26 July 2023
- Published by Springer Nature in Nature
- Vol. 620 (7973) , 386-392
Sub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ
Transient molecules in the gastrointestinal tract such as nitric oxide and hydrogen sulfide are key signals and mediators of inflammation. Owing to their highly reactive nature and extremely short lifetime in the body, these molecules are difficult to detect. Here we develop a miniaturized device that integrates genetically engineered probiotic biosensors with a custom-designed photodetector and readout chip to track these molecules in the gastrointestinal tract. Leveraging the molecular specificity of living sensors1, we genetically encoded bacteria to respond to inflammation-associated molecules by producing luminescence. Low-power electronic readout circuits2 integrated into the device convert the light emitted by the encapsulated bacteria to a wireless signal. We demonstrate in vivo biosensor monitoring in the gastrointestinal tract of small and large animal models and the integration of all components into a sub-1.4 cm3 form factor that is compatible with ingestion and capable of supporting wireless communication. With this device, diseases such as inflammatory bowel disease could be diagnosed earlier than is currently possible, and disease progression could be more accurately tracked. The wireless detection of short-lived, disease-associated molecules with our device could also support timely communication between patients and caregivers, as well as remote personalized care.
- 26 July 2023
- Published by Springer Nature in Nature
- Vol. 620 (7973) , 386-392
Top Cited PapersSub-1.4 cm3 capsule for detecting labile inflammatory biomarkers in situ
Transient molecules in the gastrointestinal tract such as nitric oxide and hydrogen sulfide are key signals and mediators of inflammation. Owing to their highly reactive nature and extremely short lifetime in the body, these molecules are difficult to detect. Here we develop a miniaturized device that integrates genetically engineered probiotic biosensors with a custom-designed photodetector and readout chip to track these molecules in the gastrointestinal tract. Leveraging the molecular specificity of living sensors1, we genetically encoded bacteria to respond to inflammation-associated molecules by producing luminescence. Low-power electronic readout circuits2 integrated into the device convert the light emitted by the encapsulated bacteria to a wireless signal. We demonstrate in vivo biosensor monitoring in the gastrointestinal tract of small and large animal models and the integration of all components into a sub-1.4 cm3 form factor that is compatible with ingestion and capable of supporting wireless communication. With this device, diseases such as inflammatory bowel disease could be diagnosed earlier than is currently possible, and disease progression could be more accurately tracked. The wireless detection of short-lived, disease-associated molecules with our device could also support timely communication between patients and caregivers, as well as remote personalized care.
- Open Access
Synthetic extremophiles: Species-specific formulations for microbial therapeutics and beyond
Microorganisms have been used for millennia to produce food and medicine and are now being developed as products themselves to treat disease and boost crop production. However, as required for these new applications, maintaining high viability throughout manufacturing, transportation and use remains a significant challenge requiring sophisticated cold-chains and packaging. In fact, we found that commercial microbial products (probiotics) provide a poor solution to this challenge, in particular for key industrial organisms like E. coli . To overcome this technological gap, we report the development of synthetic extremophiles of industrially important gram-negative bacteria ( E. coli Nissle 1917, Ensifer meliloti ), gram positive bacteria (Lactobacillus plantarum ) and yeast ( Saccharomyces boulardii ). Specifically, we developed a high throughput pipeline to define species-specific materials that allow these organisms to survive drying, elevated temperatures, organic solvents and even ionizing radiation. We enhanced the stability of E . coli Nissle 1917 by >4 orders of magnitude over commercial formulations and demonstrate the capacity to remain viable while undergoing tableting and pharmaceutical methodologies involving organic solvents. The development of synthetic materials-based enhanced stabilization stands to transform our capacity to apply micro-organisms in extreme environments including those found on Earth as well as in space. One-Sentence Summary: Fragile therapeutic bacteria can be made to survive the manufacturing extremes normally reserved for small molecule drugs.
Open AccessSynthetic extremophiles: Species-specific formulations for microbial therapeutics and beyond
Microorganisms have been used for millennia to produce food and medicine and are now being developed as products themselves to treat disease and boost crop production. However, as required for these new applications, maintaining high viability throughout manufacturing, transportation and use remains a significant challenge requiring sophisticated cold-chains and packaging. In fact, we found that commercial microbial products (probiotics) provide a poor solution to this challenge, in particular for key industrial organisms like E. coli . To overcome this technological gap, we report the development of synthetic extremophiles of industrially important gram-negative bacteria ( E. coli Nissle 1917, Ensifer meliloti ), gram positive bacteria (Lactobacillus plantarum ) and yeast ( Saccharomyces boulardii ). Specifically, we developed a high throughput pipeline to define species-specific materials that allow these organisms to survive drying, elevated temperatures, organic solvents and even ionizing radiation. We enhanced the stability of E . coli Nissle 1917 by >4 orders of magnitude over commercial formulations and demonstrate the capacity to remain viable while undergoing tableting and pharmaceutical methodologies involving organic solvents. The development of synthetic materials-based enhanced stabilization stands to transform our capacity to apply micro-organisms in extreme environments including those found on Earth as well as in space. One-Sentence Summary: Fragile therapeutic bacteria can be made to survive the manufacturing extremes normally reserved for small molecule drugs.
- 25 August 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Solid-State Circuits
- Vol. 58 (3) , 838-851
A Threshold-Based Bioluminescence Detector With a CMOS-Integrated Photodiode Array in 65 nm for a Multi-Diagnostic Ingestible Capsule
This article presents a highly miniaturized ingestible electronic capsule for biochemical detection via onboard genetically engineered biosensor bacteria. The core integrated circuit (IC) is a threshold-based bioluminescence detector with a CMOS-integrated photodiode array in a 65-nm technology that utilizes a dual-duty-cycling front end to achieve low power consumption. The implemented IC achieved 59-nW active power consumption, 25-fA/count resolution, and a 59-fA minimum detectable signal (MDS) using a calibrated optical source. The IC was then integrated with other system components into a battery-powered wireless ingestible capsule measuring just 6.5 mm thick $\times $ 12 mm diameter. We demonstrated successful detection of low-intensity bioluminescent signals from bioengineered bacterial sensors when exposed to the intestinal inflammation biomarker tetrathionate in vitro. Together, the IC and mm-scale smart pill systems demonstrate high sensitivity with low-power multiplexed measurement capability suitable for noninvasive disease diagnosis and monitoring in the gastrointestinal (GI) tract.
- 25 August 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Solid-State Circuits
- Vol. 58 (3) , 838-851
A Threshold-Based Bioluminescence Detector With a CMOS-Integrated Photodiode Array in 65 nm for a Multi-Diagnostic Ingestible Capsule
This article presents a highly miniaturized ingestible electronic capsule for biochemical detection via onboard genetically engineered biosensor bacteria. The core integrated circuit (IC) is a threshold-based bioluminescence detector with a CMOS-integrated photodiode array in a 65-nm technology that utilizes a dual-duty-cycling front end to achieve low power consumption. The implemented IC achieved 59-nW active power consumption, 25-fA/count resolution, and a 59-fA minimum detectable signal (MDS) using a calibrated optical source. The IC was then integrated with other system components into a battery-powered wireless ingestible capsule measuring just 6.5 mm thick $\times $ 12 mm diameter. We demonstrated successful detection of low-intensity bioluminescent signals from bioengineered bacterial sensors when exposed to the intestinal inflammation biomarker tetrathionate in vitro. Together, the IC and mm-scale smart pill systems demonstrate high sensitivity with low-power multiplexed measurement capability suitable for noninvasive disease diagnosis and monitoring in the gastrointestinal (GI) tract.
- Open Access
Ingestible capsule for detecting labile inflammatory biomarkers in situ
Transient molecules in the gastrointestinal (GI) tract, such as nitric oxide and hydrogen sulfide, are key signals and mediators of inflammatory bowel disease (IBD). Because these molecules are extremely short-lived in the body, they are difficult to detect. To track these reactive molecules in the GI tract, we have developed a miniaturized device that integrates genetically-engineered probiotic biosensors with a custom-designed photodetector and readout chip. Leveraging the molecular specificity of living sensors, we genetically encoded bacteria to respond to IBD-associated molecules by luminescing. Low-power electronic readout circuits (nanowatt power) integrated into the device convert the light from just 1 μL of bacterial culture into a wireless signal. We demonstrate biosensor monitoring in the GI tract of small and large animal models and integration of all components into a sub-1.4 cm 3 ingestible form factor capable of supporting wireless communication. The wireless detection of short-lived, disease-associated molecules could support earlier diagnosis of disease than is currently possible, more accurate tracking of disease progression, and more timely communication between patient and their care team supporting remote personalized care.
Open AccessIngestible capsule for detecting labile inflammatory biomarkers in situ
Transient molecules in the gastrointestinal (GI) tract, such as nitric oxide and hydrogen sulfide, are key signals and mediators of inflammatory bowel disease (IBD). Because these molecules are extremely short-lived in the body, they are difficult to detect. To track these reactive molecules in the GI tract, we have developed a miniaturized device that integrates genetically-engineered probiotic biosensors with a custom-designed photodetector and readout chip. Leveraging the molecular specificity of living sensors, we genetically encoded bacteria to respond to IBD-associated molecules by luminescing. Low-power electronic readout circuits (nanowatt power) integrated into the device convert the light from just 1 μL of bacterial culture into a wireless signal. We demonstrate biosensor monitoring in the GI tract of small and large animal models and integration of all components into a sub-1.4 cm 3 ingestible form factor capable of supporting wireless communication. The wireless detection of short-lived, disease-associated molecules could support earlier diagnosis of disease than is currently possible, more accurate tracking of disease progression, and more timely communication between patient and their care team supporting remote personalized care.